Last reviewed · How we verify
HL-040XC
HL-040XC is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.
HL-040XC is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | HL-040XC |
|---|---|
| Sponsor | HanAll BioPharma Co., Ltd. |
| Drug class | Bispecific antibody; immune checkpoint inhibitor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HL-040XC is designed to bind and block inhibitory signals on T cells by targeting multiple immune checkpoint pathways simultaneously. This dual-targeting approach aims to overcome resistance mechanisms and generate more potent anti-tumor immunity compared to single-checkpoint inhibitors. The bispecific format allows coordinated engagement of both targets on the same molecule.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia (PHASE3)
- A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HL-040XC CI brief — competitive landscape report
- HL-040XC updates RSS · CI watch RSS
- HanAll BioPharma Co., Ltd. portfolio CI